The American Journal of Medicine
Volume 121, Issue 6 , Pages 525-531 , June 2008

Racial and Ethnic Variations in Hepatocellular Carcinoma Incidence within the United States

  • Robert Wong, MD

      Affiliations

    • University of California, San Francisco School of Medicine, San Francisco
    • Corresponding Author InformationRequests for reprints should be addressed to Robert Wong, University of California, San Francisco, School of Medicine, 4306 Saint Cloud Court, Oakland, CA 94619.
    • ,
  • Douglas A. Corley, MD, PhD, MPH

      Affiliations

    • Northern California Division of Research, Oakland
    • Division of Gastroenterology, Department of Medicine, University of California, San Francisco.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576
  3. Varela M, Bruix J. Hepatocellular carcinoma in the United States: lessons from a population-based study in Medicare recipients. J Hepatology. 2006;44:8–10
  4. Bosch F, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–S16
  5. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127:S17–S26
  6. Verhoef C, Visser O, de Man RA, et al. Hepatocellular carcinoma in the Netherlands incidence, treatment, and survival patterns. Eur J Cancer. 2004;40:1530–1538
  7. West J, Wood H, Logan RF, et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer. 2006;94:1751–1758
  8. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33:62–65
  9. Cance WG, Stewart AK, Menck HR. The national cancer database report on treatment patterns for hepatocellular carcinomas. Cancer. 2000;88:912–920
  10. In:  Ries LAG,  Melbert D,  Krapcho M, et al. editor. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute; 2007;
  11. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27–S34
  12. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817–823
  13. Mcglynn KA, Tarone RE, El-Serag HB. A comparison of the trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev. 2006;15:1198–1203
  14. Chin PL, Chu DZ, Clarke KG, et al. Ethnic differences in the behavior of hepatocellular carcinoma. Cancer. 1999;85:1931–1936
  15. Di Bisceglie AM, Lyra AC, Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: Influence of ethnic status. Am J Gastroenterol. 2003;98:2060–2063
  16. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236
  17. Yuen MF, Lai CL. Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Ann Oncol. 2003;14:1463–1467
  18. Di Bisceglie AM. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology. 2004;127:S104–S107
  19. Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol. 2002;35:S86–S91
  20. Koteish A, Thuluvath PJ. Screening for hepatocellular carcinoma. J Vasc Interv Radiol. 2002;13:S185–S190
  21. Surveillance, Epidemiology, and End Results (SEER) Program Public Use CD-ROM(1973-2004). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
  22. World Health Organization. International Classification of Diseases for Oncology. 3rd ed.. Geneva, Switzerland: World Health Organization; 2000;
  23. In:  Young JL,  Roffers SD,  Ries LAG, et al. editor. SEER Summary Staging Manual—2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute; 2001;
  24. Silva IS. Cancer Epidemiology: Principles and Methods. Geneva, Switzerland: World Health Organization; 1999;
  25. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12:S294–S308
  26. Chen CJ, Yang HI, Su J, et al. REVEAL-HBV Study Group Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73
  27. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus (A prospective study of 22,707 men in Taiwan). Lancet. 1981;2:1129–1133
  28. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infection in causing hepatocellular carcinoma. Int J Cancer. 1998;75:347–354
  29. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology. 1994;106:1000–1005
  30. McMahon BJ, Alberts SR, Wainwright RB, et al. Hepatitis B-related sequelae: prospective study of 1400 hepatitis B surface antigen-positive Alaskan native carriers. Arch Intern Med. 1990;150:1051–1054
  31. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995;22:432–438
  32. Lin SY, Chang ET, So SK. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology. 2007;46:1034–1040
  33. Centers for Disease Control and Prevention. Screening for chronic hepatitis B among Asian/Pacific Islander populations—New York City, 2005. MMWR Morb Mortal Wkly Rep. 2006;55:505–509
  34. Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000;15:1356–1361
  35. de Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993;118:191–194
  36. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562
  37. Armstrong GL, Simard EP, McQuillan GM, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714
  38. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol. 2007;42:513–521
  39. Di Bisceglie AM, Simpson LH, Lotze MT, Hoofnagle JH. Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. J Clin Gastroenterol. 1994;19:222–226
  40. Hasan F, Jeffers LJ, De Medina M, et al. Hepatitis C-associated hepatocellular carcinoma. Hepatology. 1990;12:589–591
  41. Hwang SJ, Tong MJ, Lai PP, et al. Evaluation of hepatitis B and C viral markers: clinical significance in Asian and Caucasian patients with hepatocellular carcinoma in the United States of America. J Gastroenterol Hepatol. 1996;11:949–954
  42. Donato F, Tagger A, Chiesa R, et al. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case control study in Italy. Hepatology. 2003;26:579–584
  43. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan (IHIT study group. Inhibition of hepatocellular carcinoma by interferon therapy). Ann Intern Med. 1999;131:174–181
  44. Kemp W, Pianko S, Nguyen S, et al. Survival in hepatocellular carcinoma: Impact of screening and etiology of liver disease. J Gastroenterol Hepatol. 2005;20:873–881
  45. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422
  46. Yu EW, Chie WC, Chen TH. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients?. Cancer J. 2004;10:317–325
  47. Wun YT, Dickinson JA. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B. Cochrane Database Syst Rev. 2003;CD002799
  48. U.S. Census Bureau. Hispanic and Asian populations increasing faster than overall population. http://www.census.gov/Press-Release/www/releases/archives/race/001839.htmlAccessed October 24, 2007

PII: S0002-9343(08)00248-9

doi: 10.1016/j.amjmed.2008.03.005

The American Journal of Medicine
Volume 121, Issue 6 , Pages 525-531 , June 2008

Article Tools

* Image Usage & Resolution